摘要:
The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
摘要:
The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
摘要:
Provided are methods of treatment for inflammatory and autoimmune disorders of the central nervous system and gastrointestinal tract. Also provided are methods of diagnosis.
摘要:
FIG. 1 is a front elevation view of a smartwatch case showing the new design; FIG. 2 is a back elevation view thereof; FIG. 3 is a left-side view thereof; FIG. 4 is a right-side view thereof; FIG. 5 is a top plan view thereof; FIG. 6 is a bottom plan view thereof; FIG. 7 is a perspective view thereof; and, FIG. 8 is another perspective view thereof. The broken lines depict portions of the smartwatch case and form no part of the claimed design.
摘要:
A method of forming an array of nanostructures includes forming a plurality of seed points on a surface of a substrate, and growing masks from the seed points to create masked regions of the substrate underlying the masks. A remainder of the substrate comprises an unmasked region. Each mask and masked region increase in size with growth time while the unmasked region of the substrate decreases in size. During the growing, the unmasked region is etched to remove material from the substrate in a depth direction, and, simultaneously, unetched structures are formed from the masked regions of the substrate underlying the masks. Each of the unetched structures has a lateral size that increases with depth.
摘要:
Provided are a camptothecin compound containing 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as the preparation method and use thereof. In general formula I, R1 is H, a C1˜C3 alkyl, acetyl or propionyl; R2 is H, a C1˜C6 alkyl, a C3˜C6 cycloalkyl, piperidyl; or a C1˜C6 alkyl substituted by an amino; R3 is H, a C1˜C3 alkyl, or a C1˜C6 alkyl substituted by an amino; R4 is H, a hydroxyl, or a C1˜C6 alkoxy; R5 is H, or a C1˜C6 alkoxyl; or R4 and R5 are linked to each other to form —OCH2O— or —OCH2CH2O—. The compound has good anti-tumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.
摘要:
The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.
摘要:
The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.